Anagrelide

Drug Profile

Anagrelide

Alternative Names: Agrelid; Agrylin; Anagrelide hydrochloride; BL 4162A; BMY 2653801; KRN654; SPD422; Xagrid

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Shire
  • Class 3-ring heterocyclic compounds; Antiplatelets; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 25 Nov 2014 Launched for Thrombocytosis in Japan (PO)
  • 26 Sep 2014 Registered for Thrombocytosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top